Faculty Opinions recommendation of Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes.

Author(s):  
Caetano Reis e Sousa
Keyword(s):  
2006 ◽  
Vol 7 (6) ◽  
pp. 663-671 ◽  
Author(s):  
Shalin H Naik ◽  
Donald Metcalf ◽  
Annemarie van Nieuwenhuijze ◽  
Ian Wicks ◽  
Li Wu ◽  
...  
Keyword(s):  

2003 ◽  
Vol 987 (1) ◽  
pp. 15-25 ◽  
Author(s):  
RALPH M. STEINMAN ◽  
DANIEL HAWIGER ◽  
KANG LIU ◽  
LAURA BONIFAZ ◽  
DAVID BONNYAY ◽  
...  

2006 ◽  
Vol 203 (12) ◽  
pp. 2627-2638 ◽  
Author(s):  
Milena Bogunovic ◽  
Florent Ginhoux ◽  
Amy Wagers ◽  
Martine Loubeau ◽  
Luis M. Isola ◽  
...  

In this study, we explored dermal dendritic cell (DC) homeostasis in mice and humans both in the steady state and after hematopoietic cell transplantation. We discovered that dermal DCs proliferate in situ in mice and human quiescent dermis. In parabiotic mice with separate organs but shared blood circulation, the majority of dermal DCs failed to be replaced by circulating precursors for >6 mo. In lethally irradiated mice injected with donor congenic bone marrow (BM) cells, a subset of recipient DCs remained in the dermis and proliferated locally throughout life. Consistent with these findings, a large proportion of recipient dermal DCs remained in patients' skin after allogeneic hematopoietic cell transplantation, despite complete donor BM chimerism. Collectively, our results oppose the traditional view that DCs are nondividing terminally differentiated cells maintained by circulating precursors and support the new paradigm that tissue DCs have local proliferative properties that control their homeostasis in the steady state. Given the role of residual host tissue DCs in transplant immune reactions, these results suggest that dermal DC homeostasis may contribute to the development of cutaneous graft-versus-host disease in clinical transplantation.


2008 ◽  
Vol 180 (7) ◽  
pp. 4679-4686 ◽  
Author(s):  
Magali Terme ◽  
Nathalie Chaput ◽  
Behazine Combadiere ◽  
Averil Ma ◽  
Toshiaki Ohteki ◽  
...  

2006 ◽  
Vol 177 (9) ◽  
pp. 5997-6006 ◽  
Author(s):  
Laurence Macia ◽  
Myriam Delacre ◽  
Georges Abboud ◽  
Tan-Sothéa Ouk ◽  
Anne Delanoye ◽  
...  

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii110-ii110
Author(s):  
Jay Bowman-Kirigin ◽  
Dale Kobayashi ◽  
Alexandra Livingstone ◽  
Brian Saunders ◽  
Max Schaettler ◽  
...  

Abstract The antigen presenting cell that primes T cells in the central nervous system (CNS) remains unknown. Outside the CNS, the conventional dendritic cell 1 (cDC1) subset presents antigen to and primes CD8 T cells. However, the steady-state CNS parenchyma is relatively devoid of all dendritic cell subsets, including cDC1. cDC1 are required for anti-tumor immunity a variety of other tumor types, but their role CNS tumors remains undefined. Using the orthotopic preclinical glioblastoma models, GL261 and CT2A, we characterized the role of cDC1 in the CNS anti-tumor immune response. While cDC1 are absent in the steady state brain, tumor presence drove recruitment of cDC1 into extravascular spaces within the tumor and adjacent brain parenchyma. We further found that while GL261-bearing wildtype mice experienced survival benefit following anti-PDL1 checkpoint blockade treatment, mice with cDC1 genetically deleted experienced no survival benefit. cDC1-deficient mice completely lacked neoantigen-specific CD8 T cells against the endogenously-primed GL261-neoantigen mutant Imp3, and possessed broad CD8 effector T cell defects compared to wild type mice. Furthermore, using a fluorescent tumor-associated reporter, we detected tumor-derived material within dendritic cells from the tumor, the lymphatic vessel-containing dura, and the cervical lymph nodes. We observed the human cDC1-equivalent CD141+ cDC within human brain tumors (not limited to GBM) and dura as well. We used the GBM-specific reporter, 5-aminoilevulinic acid/protoporphyrin IX (PPIX) fluorescent metabolite to resect the tumor, and observed PPIX specifically in conventional dendritic cell subsets that had infiltrated the resected tumor, but not within those same cell subsets in the periphery, nor in T cells within the tumor. These findings comport with the canonical understanding that cDC1 uptake antigen at the effector site and migrate to draining lymph nodes to prime effector CD8 T cells, and highlight the significant role that cDC1 play in CNS anti-tumor immunity in mice and humans.


Blood ◽  
2012 ◽  
Vol 120 (22) ◽  
pp. 4363-4373 ◽  
Author(s):  
Haiyan S. Li ◽  
Cliff Y. Yang ◽  
Kalyan C. Nallaparaju ◽  
Huiyuan Zhang ◽  
Yong-Jun Liu ◽  
...  

Abstract Cytokines and transcription factors play key roles in dendritic cell (DC) development, yet information about regulatory interactions between these signals remains limited. Here we show that the cytokines GM-CSF and Flt3L induce the transcriptional mediators Id2 and E2-2 and control DC lineage diversification by STAT–dependent pathways. We found that STAT5 is required for tissue CD103+ DC generation and plasmacytoid DC (pDC) suppression in steady state or response to GM-CSF. STAT5 stimulates GM-CSF–dependent expression of Id2, which controls CD103+ DC production and pDC inhibition. By contrast, pDCs, but not CD103+ DCs, are dependent on STAT3. Consistently, STAT3 stimulates Flt3L-responsive expression of the pDC regulator Tcf4 (E2-2). These data suggest that STATs contribute to DC development by controlling transcription factors involved in lineage differentiation.


Sign in / Sign up

Export Citation Format

Share Document